NCT02052583

Brief Summary

Cardiac arrest is a major public health problem, with 700 000 cases per year , and a survival ranging from 4 to 33%. The post- anoxic encephalopathy remains the most serious complication with only a third of survivors . It is due to a series of phenomena involving microcirculation disorders . Cerebral oximetry is a new technique to evaluate the microcirculatory status . To this day it is used in cardiovascular surgery at risk of cerebral hypoperfusion where desaturation of cerebral oximetry is synonymous with ischemia and microcirculatory disorders. Therapeutic hypothermia is the only treatment improves the outcome of patients after extra- hospital cardiac arrest resuscitation . Its mechanisms of action seem to change all the phenomena responsible for microcirculatory reperfusion disorders . Currently it is recommended to practice hypothermia between 32 and 34 ° C. However, a recent study suggests a superiority of hypothermia at 32 ° C rather than 34 ° C. The hypothesis of this study is that cerebral oximetry value will be different in patients subjected to two different levels of therapeutic hypothermia in the aftermath of an extra- hospital cardiac arrest. These data allow a better understanding of the mechanisms underlying the benefit of this technique.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
44

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Mar 2014

Typical duration for not_applicable

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 20, 2013

Completed
3 months until next milestone

First Posted

Study publicly available on registry

February 3, 2014

Completed
2 months until next milestone

Study Start

First participant enrolled

March 28, 2014

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 9, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 9, 2017

Completed
Last Updated

March 22, 2023

Status Verified

August 1, 2018

Enrollment Period

3 years

First QC Date

November 20, 2013

Last Update Submit

March 21, 2023

Conditions

Keywords

Cardiac arrestOxymetryHypothermia

Outcome Measures

Primary Outcomes (1)

  • Mesure of cerebral oximetry

    During the first 48 hours of hospitalization, we will collect the cerebral oximetry values in the two cerebral hemispheres.

    8 times during the first 48 hours of hospitalization

Secondary Outcomes (4)

  • The cerebral oximetry values (average of the two hemispheres) will be compared between patients with good and poor neurological outcome.

    8 times during the first 48 hours of hospitalization

  • For each level of therapeutic hypothermia the cerebral oximetry values will be compared between patients with good and poor becoming

    baseline, when target temperature is reached, 6 hours, 12 hours, 18 hours, 24 hours, when 37°C is reached

  • Outcome of patients

    6 months after hospitalization

  • Mesure of lactate

    4 times during the first 48 hours of hospitalization

Study Arms (2)

34°C

EXPERIMENTAL

therapeutic hypothermia at 34 ° C

Procedure: therapeutic hypothermia at 34 ° C

32°C

EXPERIMENTAL

therapeutic hypothermia at 32 ° C

Procedure: therapeutic hypothermia at 32 ° C

Interventions

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient presented with an extra-hospital cardiac arrest resuscitation and to benefit from therapeutic hypothermia using a servo system to its temperature (CoolGard 3000 ® system)
  • Age\> 18 years and \<80 years

You may not qualify if:

  • Major Patient protected by law
  • Private person administrative or judicial freedom
  • Neurological or traumatic cause of cardiac arrest
  • Pregnancy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

CH de Fréjus-Saint Raphael

Fréjus, 83608, France

Location

CHU de Nice - Hôpital Saint Roch

Nice, 06000, France

Location

MeSH Terms

Conditions

Heart ArrestHypothermia

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesBody Temperature ChangesSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Jean-Christophe ORBAN, MD

    Centre Hospitalier Universitaire de Nice

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 20, 2013

First Posted

February 3, 2014

Study Start

March 28, 2014

Primary Completion

March 9, 2017

Study Completion

March 9, 2017

Last Updated

March 22, 2023

Record last verified: 2018-08

Locations